Neuropeptides in eating disorders

CNS Spectrums

Volumn 9, Issue 7, 2004, Pages 516-522

  Jimerson, David C ^a,b   Wolfe, Barbara E ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APPETITE STIMULANT; CHOLECYSTOKININ; GHRELIN; NEUROPEPTIDE; NEUROPEPTIDE Y; OPIATE PEPTIDE; PEPTIDE YY;

ANOREXIA NERVOSA; BODY WEIGHT; BULIMIA; CLINICAL TRIAL; DIET RESTRICTION; EATING DISORDER; FEEDING BEHAVIOR; HUMAN; HYPOTHALAMUS; INTESTINE; NONHUMAN; NUTRITION; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; PUBLIC HEALTH; REVIEW; SATIETY;

EID: 3342938172     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900009603     Document Type: Review

References (85)

1. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346: 591-602.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed-text rev. Washington, DC: American Psychiatric Association; 2000.
3. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763-770.
4. Tecott LH, Nestler EJ. Neurobehavioral assessment in the information age. Nat Neurosci. 2004;7:462-466.
5. Heinrichs SC, Richard D. The role of corticotropin-releasing factor and urocortin in the modulation of ingestive behavior. Neuropeptides. 1999;33:350-359.
6. Kaye WH, Gwirtsman HE, George DT, et al. Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J Clin Endocrinol Metab. 1987;64:203-208.
7. Kaye WH. Neuropeptide abnormalities in anorexia nervosa. Psychiatry Res. 1996;62:65-74.
8. Stoving RK, Hangaard J, Hansen-Nord M, Hagen C. A review of endocrine changes in anorexia nervosa. J Psychiatr Res. 1999;33:139-152.
9. Kissileff HR, Wentzlaff TH, Guss JL, Walsh BT, Devlin MJ, Thornton JC. A direct measure of satiety disturbance in patients with bulimia nervosa. Physiol Behav. 1996;60:1077-1085.
10. Jimerson DC, Wolfe BE. Eating disorders: neurobiology and symptomatology. In: Asbury AK, McKhann GM, McDonald WI, Goadsby PJ, McArthur JC, eds. Diseases of the Nervous System: Clinical Neuroscience and Therapeutic Principles. 3rd ed. Cambridge, UK: Cambridge University Press; 2002:8O8-815.
11. Sunday SR, Halmi KA. Micro- and macroanalyses of patterns within a meal in anorexia and bulimia nervosa. Appetite. 1996;26:21-36.
12. Woods SC, Schwartz MW, Baskin DG, Seeley RJ. Food intake and the regulation of body weight. Annu Rev Psychol. 2000;51:255-277.
13. Zigman JM, Elmquist JK. Minireview: From anorexia to obesity-the yin and yang of body weight control. Endocrinology. 2003;144:3749-3756.
14. Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC. Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr. 1999;69:584-596.
15. American Psychiatric Association Workgroup on Eating Disorders. Practice guideline for the treatment of patients with eating disorders [revision]. Am J Psychiatry. 2000;157:1-39.
16. Kaye WH, Strober M, Jimerson DC. The neurobiology of eating disorders. In: Charney DS, Nestler EJ, eds. The Neurobiology of Mental Illness. Oxford: Oxford University Press; 2004:1112-1128.
17. Mantzoros C, Flier JS, Lesem MD, Brewerton TD, Jimerson DC. Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status and potential role in resistance to weight gain. J Clin Endocrinol Metab. 1997;82:1845-1851.
18. Neary NM, Small CJ, Bloom SR. Gut and mind. Gut. 2003;52:918-921.
19. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982;296:659-660.
20. Gehlert DR. Role of hypothalamic neuropeptide Y in feeding and obesity. Neuropeptides. 1999;33:329-338.
21. Leibowitz SF, Alexander JT. Analysis of neuropeptide Y-induced feeding; dissociation of Y1 and Y2 receptor effects on natural meal patterns. Peptides. 1991;12:1251-1260.
22. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science. 1996;274:1704-1707.
23. Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci U S A. 1991;88:10931-10935.
24. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology. 1993;133:1753-1758.
25. Kaye WH, Berrettini W, Gwirtsman H, George DT. Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Arch Gen Psychiatry. 1990;47:548-556.
26. Gendall KA, Kaye WH, Altemus M, McConaha CW, La Via MC. Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients. Biol Psychiatry. 1999;46:292-299.
27. Nedvidkova J, Papezova H, Haluzik M, Schreiber V. Interaction between serum leptin levels and hypothalamo-hypophyseal-thyroid axis in patients with anorexia nervosa. Endocr Res. 2000;26:219-230.
28. Baranowska B, Wolinska-Witort E, Wasilewska-Dziubinska E, Roguski K, Chmielowska M. Plasma leptin, neuropeptide Y (NPY) and galanin concentrations in bulimia nervosa and in anorexia nervosa. Neuroendocrinol Lett. 2001;22:356-358.
29. Levine AS, Morley JE, Gosnell BA, Billington CJ, Bartness TJ. Opioids and consummatory behavior. Brain Res Bull. 1985;14:663-672.
30. Glass MJ, Billington CJ, Levine AS. Opioids and food intake: distributed functional neural pathways? Neuropeptides. 1999;33:360-368.
31. Zhang M, Gosnell BA, Kelley AE. Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. J Pharmacol Exp Ther. 1998;285:908-914.
32. de Zwaan M, Mitchell JE. Opiate antagonists and eating behavior in humans: a review. J Clin Pharmacol. 1992;32:1060-1072.
33. Gerner RH, Sharp B. CSF beta-endorphin-immunoreactivity in normal, schizophrenic, depressed, manic and anorexic subjects. Brain Res. 1982;237:244-247.
34. Lesem MD, Berrettini WH, Kaye WH, Jimerson DC. Measurement of CSF dynorphin A 1-8 immunoreactivity in anorexia nervosa and normal-weight bulimia. Biol Psychiatry. 1991;29:244-252.
35. Baranowska B. Are disturbances in opioid and adrenergic systems involved in the hormonal dysfunction of anorexia nervosa? Psychoneuroendocrinology. 1990;15:371-379.
36. Brambilla F, Ferrari E, Petraglia F, Facchinetti F, Catalano M, Genazzani AR. Peripheral opioid secretory pattern in anorexia nervosa. Psychiatry Res. 1991;39:115-127.
37. Brambilla F, Brunetta M, Peirone A, Perna G, Sacerdote P, Manfredi B, Panerai AE. T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa. Psychiatry Res. 1995;59:43-50.
38. Brewerton TD, Lydiard RB, Laraia MT, Shook JE, Ballenger JC. CSF beta-endorphin and dynorphin in bulimia nervosa. Am J Psychiatry. 1992;149: 1086-1090.
39. Waller DA, Kiser RS, Hardy BW, Fuchs I, Feigenbaum LP, Uauy R. Eating behavior and plasma beta-endorphin in bulimia. Am J Clin Nutr. 1986;44:20-23.
40. Brambilla F, Brunetta M, Draisci A, et al. T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa. Psychiatry Res. 1995;59:51-56.
41. Mitchell JE, Laine DE, Morley JE, Levine AS. Naloxone but not CCK-8 may attenuate binge-eating behavior in patients with the bulimia syndrome. Biol Psychiatry. 1986;21:1399-406.
42. Vergoni AV, Bertolini A. Role of melanocortins in the central control of feeding. Eur J Pharmacol. 2000;405:25-32.
43. Koegler FH, Grove KL, Schiffmacher A, Smith MS, Cameron JL. Central melanocortin receptors mediate changes in food intake in the rhesus macaque. Endocrinology. 2001;142:2586-2592.
44. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science. 2002;297:609-611.
45. Farooqi IS, Yeo GS, O'Rahilly S. Binge eating as a phenotype of melanocortin 4 receptor gene mutations. N Engl J Med. 2003;349:606-609.
46. Branson R, Potoczna N, Kral JG, Lentes KU, Hoehe MR, Horber FF. Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N Engl J Med. 2003;348:1096-1103.
47. Fetissov SO, Hallman J, Oreland L, et al. Autoantibodies against alpha -MSH, ACTH, and LHRH in anorexia and bulimia nervosa patients. Proc Natl Acad Sci U S A. 2002;99:17155-17160.
48. Lu D, Willard D, Patel IR, et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature. 1994;371:799-802.
49. Kas MJ, van Dijk G, Scheurink AJ, Adan RA. Agouti-related protein prevents self-starvation. Mol Psychiatry. 2003;8:235-240.
50. Vink T, Hinney A, van Elburg AA, et al. Association between an agouti-related protein gene polymorphism and anorexia nervosa. Mol Psychiatry. 2001;6:325-328.
51. Jimerson DC, Mantzoros C, Wolfe BE, Metzger ED. Decreased serum leptin in bulimia nervosa. J Clin Endocrinol Metab. 2000;85:4511-4514.
52. Jimerson DC. Leptin and the neurobiology of eating disorders. J Lab Clin Med. 2002;139:70-71.
53. Pannacciulli N, Vettor R, Milan G, et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab. 2003;88:1748-1752.
54. Delporte ML, Brichard SM, Hermans MP, Beguin C, Lambert M. Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol (Oxf). 2003;58:22-29.
55. Iwahashi H, Funahashi T, Kurokawa N, et al. Plasma adiponectin levels in women with anorexia nervosa. Horm Metab Res. 2003;35:537-540.
56. Wolfe BE, Jimerson DC, Orlova C, Mantzoros CS. Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol. In press.
57. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol. 1973;84:488-495.
58. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr. 1981;34:154-160.
59. Moran TH, Kinzig KP. Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol. 2004;286:G183-G188.
60. Blevins JE, Stanley BG, Reidelberger RD. Brain regions where cholecystokinin suppresses feeding in rats. Brain Res. 2000;860:1-10.
61. Gerner RH, Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res. 1982;238:298-302.
62. Geracioti TD Jr, Liddle RA, Altemus M, Demitrack MA, Gold PW. Regulation of appetite and cholecystokinin secretion in anorexia nervosa. Am J Psychiatry. 1992;149:958-961.
63. Pirke KM, Kellner MB, Friess E, Krieg JC, Fichter MM. Satiety and cholecystokinin. Int J Eat Disord 1994;15:63-69.
64. Lydiard RB, Brewerton TD, Fossey MD, et al. CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. Am J Psychiatry. 1993;150:1099-1101.
65. Geracioti TD Jr, Liddle RA. Impaired cholecystokinin secretion in bulimia nervosa. N Engl J Med. 1988;319:683-688.
66. Devlin MJ, Walsh BT, Guss JL, Kissileff HR, Liddle RA, Petkova E. Postprandial cholecystokinin release and gastric emptying in patients with bulimia nervosa. Am J Clin Nutr. 1997;65:114-120.
67. Geliebter A, Melton PM, McCray RS, Gallagher DR, Gage D, Hashim SA. Gastric capacity, gastric emptying, and test-meal intake in normal and bulimic women. Am J Clin Nutr. 1992;56:656-661.
68. Walsh BT, Zimmerli E, Devlin MJ, Guss J, Kissileff HR. A disturbance of gastric function in bulimia nervosa. Biol Psychiatry 2003;54:929-933.
69. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Erdocrinol Metab. 2001;86:4753-4758.
70. Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y (NPY) and agouti-related protein (AgRP). Endocrinology 2004;145:2607-2612.
71. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992-5995.
72. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-1630.
73. Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001;145:669-673.
74. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87:240-244.
75. Tanaka M, Naruo T, Nagai N, et al. Habitual binge/purge behavior influences circulating ghrelin levels in eating disorders. J Psychiatr Res. 2003;37:17-22.
76. Soriano-Guillén L, Barrios V, Campos-Barros Á, Argente J. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. J Pediatr. 2004;144:36-42.
77. Tolle V, Kadem M, Bluet-Pajot MT, et al. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab. 2003;88:109-116.
78. Tanaka M, Naruo T, Yasuhara D, et al. Fasting plasma ghrelin levels in subtypes of anorexia nervosa. Psychoneuroendocrinology. 2003;28:829-835.
79. Nedvídková J, Krykorková I, Barták V, et al. Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. J Clin Endocrinol Metab. 2003;88:1678-1682.
80. Nakai Y, Hosoda H, Nin K, et al. Plasma levels of active form of ghrelin during oral glucose tolerance test in patients with anorexia nervosa. Eur J Endocrinol. 2003;149:R1-R3.
81. Tanaka M, Tatebe Y, Nakahara T, et al. Eating pattern and the effect of oral glucose on ghrelin and insulin secretion in patients with anorexia nervosa. Clin Endocrinol (Oxf). 2003;59:574-579.
82. Tanaka M, Naruo T, Muranaga T, et al. Increased fasting plasma ghrelin levels in patients with bulimia nervosa. EurJ Endocrinol. 2002; 146:R1-R3.
83. Monteleone P, Martiadis V, Fabrazzo M, Serritella C, Maj M. Ghrelin and leptin responses to food ingestion in bulimia nervosa: implications for binge-eating and compensatory behaviors. Psychol Med. 2003;33:1387-1394.
84. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418:650-654.
85. 3-36. N Engl J Med. 2003;349:941-948.